Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Net Margin
Adaptimmune Therapeutics PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | UK |
Market Cap | 316.9m USD |
Net Margin |
-189%
|
Country | US |
Market Cap | 289.2B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 171.1B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 112.7B USD |
Net Margin |
37%
|
Country | US |
Market Cap | 107.8B USD |
Net Margin |
29%
|
Country | AU |
Market Cap | 136.7B AUD |
Net Margin |
17%
|
Country | US |
Market Cap | 83.5B USD |
Net Margin |
2%
|
Country | US |
Market Cap | 49.4B USD |
Net Margin |
-116%
|
Country | US |
Market Cap | 43.1B USD |
Net Margin |
-33%
|
Country | US |
Market Cap | 34.3B USD |
Net Margin |
12%
|
Country | KR |
Market Cap | 39.6T KRW |
Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for Adaptimmune Therapeutics PLC.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Adaptimmune Therapeutics PLC's most recent financial statements, the company has Net Margin of -188.9%.